Teladoc Health, Inc. (TDOC) Stock Price & Analysis
Teladoc Health, Inc. (TDOC) closed at USD 6.32 on Thursday, October 22, 2026, up 0.32% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 6.3; the Oct 22, 2026 session ranged USD 6.29–6.41 on volume of 2,816,927 shares. Market capitalization is $1.15B, with a 52-week range of USD 4.4–9.89 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TDOC.md
Key facts (TDOC)
- Analysts: Hold (mean 2.70 on a 1–5 scale) (23 analysts), mean target USD 7.47 (range 5.5–10.5).
- Total return with dividends: 1Y -26.5% vs S&P 500 +14.9%; 5Y -95.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD -0.19, revenue estimate $590M.
Analysts (TDOC)
Consensus Hold (mean 2.70 on a 1–5 scale), 23 analysts; mean target USD 7.47 (low 5.5, high 10.5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | Citigroup | Target lowered | Neutral | $11 → $7.5 |
| 2026-07-30 | Canaccord Genuity | Target lowered | Buy | $11 → $10 |
| 2026-07-30 | Evercore ISI Group | Target lowered | In-Line | $10 → $7.5 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $10 → $11 |
| 2026-07-07 | B of A Securities | Target raised | Buy | $9 → $10.5 |
Total return (dividends reinvested) (TDOC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -26.5% | -95.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -26.6% | -45.9% |
| Volatility (annualized) | 63.0% | 65.7% |
| Max drawdown | -52.8% (Oct 2025→Feb 2026) | -96.9% (Oct 2021→Feb 2026) |
Companies that name TDOC in their SEC reports
| Relationship to TDOC | Company | Filing | Sentence |
|---|---|---|---|
| partner | Hinge Health, Inc. (HNGE) | 10-K Mar 3, 2026 | “As of December 31, 2025, we had over 60 partners, consisting of health plans, PBMs, TPAs, and other ecosystem partners, including Accolade, Inc., Carrum Health, Inc., Castlight Health, Inc., Employer Direct Healthcare, LLC doing business as Lantern Specialty Care, Personify Health, Inc., Progny, Inc., Quantum Health, Inc., Teladoc Health, Inc., and Vera Whole Health, Inc. Our partners include the five largest nati…” |
TDOC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.19 | $-0.15 | +24.4% | $590.5M | 3 |
| Next quarter (ends Dec 2026) | $-0.09 | $-0.11 | -21.2% | $600.1M | 3 |
| Current fiscal year (ends Dec 2026) | $-0.79 | $-0.79 | -0.1% | $2.42B | 3 |
| Next fiscal year (ends Dec 2027) | $-0.72 | $-0.65 | +11.7% | $2.40B | 3 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 6.32 |
|---|---|
| Change | ▲ 0.32% (up) |
| Previous Close | USD 6.3 |
| Open | USD 6.28 |
| Day Range | USD 6.29 – 6.41 |
| 52-Week Range | USD 4.4 – 9.89 |
| Volume | 2,816,927 shares |
| Market Cap | $1.15B |
| Exchange | NYQ |
Technical Analysis (TDOC)
Nexqual's technical model rates TDOC "NEUTRAL" based on 4 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 58.7 (neutral) |
| vs SMA50 | Above (USD 6.17) |
| MACD | -0.03 (negative) |
Analyst Ratings (TDOC)
Wall Street analysts rate TDOC "Hold" based on 23 analysts, with a mean price target of USD 7.47 (range USD 5.5–10.5), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 7.47 |
| High Target | USD 10.5 |
| Low Target | USD 5.5 |
| Buy / Hold / Sell | 6 / 17 / 0 |
Earnings (TDOC)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $590.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.23 ▲ beat |
| 2026-03-31 | USD -0.28 vs est -0.39 ▲ beat |
| 2025-12-31 | USD -0.1 vs est -0.22 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.31 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (TDOC)
| Total Revenue | $2.49B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -4.00% |
| Gross Margin | +68.97% |
| Operating Margin | -5.68% |
| Profit Margin | -7.13% |
| ROE | -12.98% |
| Debt / Equity | 0.79 |
| Current Ratio | 0.83 |
| Total Cash | $774.35M |
| Total Debt | $1.04B |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $285.46M (11.3% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (TDOC)
Nexqual rates Teladoc Health, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 69%, operating -6% (last 12 months) |
| Balance Sheet | Weak — $774M cash vs $1.04B debt |
| Cash Flow | Solid — FCF $285M (FY ended Dec 2025, 10-K), 11% margin |
| Efficiency | Critical — ROE -13%, ROA -3.2% |
Ownership (TDOC)
| Insider Ownership | +0.74% |
|---|---|
| Institutional Ownership | +88.77% |
| Shares Outstanding | 181.68M |
| Float | 180.43M |
| Short % of Float | +16.65% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (TDOC)
Teladoc Health, Inc. is led by Charles Divita III, CEO & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| CEO & Director | Charles Divita III |
|---|---|
| President of International | Carlos Nueno |
| President of U.S. Group Health | Kelly M. Bliss |
| Chief Financial Officer | Michael Fitzgerald Grasher |
| Chief Technology Officer | Dave Ross |
Major Backers & Investors (TDOC)
Notable institutional backers of Teladoc Health, Inc. include Point72 Asset Management, L.P., Renaissance Technologies, Voss Capital, LP, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Point72 Asset Management, L.P. | 4.54% |
| Renaissance Technologies | 4.44% |
| Voss Capital, LP | 4.43% |
| American Century Companies Inc | 2.69% |
| PIMCO Equity Series-PIMCO RAE US Small Fund | 1.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.36% |
| BlackRock | 8.93% |
| Dimensional Fund Advisors | 4.06% |
| State Street | 2.73% |
| Allianz Asset Management GmbH | 2.57% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OMDA | Omada Health, Inc. | USD 18.98 | ▼ 3.46% |
| GDRX | GoodRx Holdings, Inc. | USD 3.62 | ▲ 1.4% |
| HSTM | HealthStream, Inc. | USD 34.59 | ▲ 3.22% |
| CERT | Certara, Inc. | USD 10.09 | ▼ 0.88% |
| OMCL | Omnicell, Inc. | USD 37.1 | ▲ 2.09% |
| SDGR | Schrodinger, Inc. | USD 22.6 | ▼ 5.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt